Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Palmoplantaris Pustulosis

erlotinib hydrochloride has been researched along with Palmoplantaris Pustulosis in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Augustin, M; Goepel, L; Jacobi, A; Radtke, MA1
Li, C; Li, Q; Liu, J; Liu, Y; Peng, L; Wang, H; Wu, J; Xia, L; Xia, Y1
Bagde, A; Boakye, CHA; Doddapaneni, R; Marepally, S; Patel, K; Singh, M1
Brown, CW; Campbell, TM1
Griesinger, F; Overbeck, TR1

Reviews

1 review(s) available for erlotinib hydrochloride and Palmoplantaris Pustulosis

ArticleYear
Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?.
    Dermatology (Basel, Switzerland), 2012, Volume: 225, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Treatment Outcome

2012

Other Studies

4 other study(ies) available for erlotinib hydrochloride and Palmoplantaris Pustulosis

ArticleYear
Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Psoriasis; Severity of Illness Index

2018
Fn14 deficiency ameliorates psoriasis-like skin disease in a murine model.
    Cell death & disease, 2018, 07-23, Volume: 9, Issue:8

    Topics: Animals; Cell Proliferation; Chemokine CCL5; Cytokines; Disease Models, Animal; Erlotinib Hydrochloride; Humans; Interleukin-6; Interleukin-8; Keratin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Knockout; Psoriasis; RNA Interference; RNA, Small Interfering; Skin; TWEAK Receptor; Up-Regulation

2018
Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, 01-28, Volume: 246

    Topics: Administration, Cutaneous; Animals; Drug Delivery Systems; Erlotinib Hydrochloride; Gene Transfer Techniques; HEK293 Cells; Humans; Interleukin-1; Male; Mice, Inbred C57BL; Protein Kinase Inhibitors; Psoriasis; RNA, Small Interfering; RNAi Therapeutics; Skin

2017
Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
    Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:12

    Topics: Acneiform Eruptions; Aged; Drug Eruptions; Erlotinib Hydrochloride; Folliculitis; Humans; Male; Protein Kinase Inhibitors; Psoriasis; Quinazolines

2008